CJC-1295 (no DAC) + Ipamorelin Blend
5 mg / 5 mg
Modified GRF 1-29 + Ipamorelin
CJC-1295 (no DAC) + Ipamorelin Blend
GHRH + GHRP blend for synergistic growth hormone secretion research.
Prices in AUD. Tax included.
Research Use Only: FOR LABORATORY RESEARCH USE ONLY. Not for human consumption, injection, or therapeutic use. All products are sold strictly as research chemicals. By purchasing, you confirm you are 18+ and agree to use products solely for legitimate research purposes.
Description
This blend combines CJC-1295 without DAC (also known as Modified GRF 1-29), a growth hormone-releasing hormone analogue, with Ipamorelin, a selective growth hormone-releasing peptide. The combination is widely used in research protocols studying pulsatile GH release patterns.
Specifications
- SKU
- CJCIPA-10MG
- Size
- 5 mg / 5 mg
- Form
- Lyophilised Powder
- Purity
- >99%
- Storage
- -20°C (lyophilised), 2-8°C (reconstituted)
- Shipping
- Australia Post — 3–5 business days
Research Summary
Research demonstrates that combining a GHRH analogue (CJC-1295) with a GHRP (Ipamorelin) produces synergistic GH release significantly greater than either peptide alone. Ipamorelin is notably selective — it does not significantly affect cortisol, prolactin, or ACTH levels, making it preferred for controlled research settings.
Testing Protocol
- HPLC Purity Analysis
- Mass Spectrometry Identity Verification
- Endotoxin Screening (LAL Test)